The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...

RXRX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.20 since the market last closed. This is a 4.96% ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...